GC Pharma Unveils AI-Driven mRNA-LNP Platform, Advances COVID-19 Vaccine Toward Phase 2 Trial
Key Insights
GC Green Cross (search) presented its proprietary mRNA-LNP vaccine platform at the Seoul Pandemic X Summit 2026, highlighting AI-driven codon optimization and lipid nanoparticle design technologies.
The company's COVID-19 (search) mRNA vaccine candidate demonstrated immune responses comparable to existing global vaccines in non-clinical studies, with supportive safety data.
GC Green Cross (search) completed first subject dosing in a Phase 1 trial in January 2026 and plans to submit a Phase 2 clinical trial plan in the second half of this year.
GC Green Cross (search) has publicly detailed its mRNA vaccine development strategy at the Seoul Pandemic X Summit 2026, unveiling a proprietary mRNA-LNP platform (search) that leverages artificial intelligence deep learning to accelerate vaccine design and manufacturing. The company, which completed first-patient dosing in a Phase 1 clinical trial of its COVID-19 (search) mRNA vaccine candidate at the end of January 2026, now plans to submit a Phase 2 clinical trial plan in the second half of this year.
The Seoul Pandemic X Summit, held on June 10, 2026, convened international stakeholders to discuss cooperation frameworks for rapid vaccine development and supply in response to future infectious disease pandemics. GC Green Cross (search) used the forum to showcase both its technological platform and the preclinical data supporting its lead COVID-19 (search) vaccine candidate.
AI-Powered Platform Design
At the core of GC Green Cross (search)'s approach is an mRNA-LNP platform (search) that has been under continuous development since 2019. The platform integrates two key AI-driven technologies: a codon optimization software that designs mRNA sequences for maximal protein expression efficiency in human cells, and an AI-based optimization system for lipid nanoparticle (LNP) lipid structure and composition.
The codon optimization process is designed so that human cells can read mRNA genetic information more easily and quickly, enabling a strong immune response even with a small amount of vaccine. LNPs serve as the delivery vehicle, encapsulating the fragile mRNA in lipid-based nano-sized particles to protect it from degradation and facilitate delivery to target cells.
Preclinical Results and Clinical Progress
According to GC Green Cross (search), the COVID-19 (search) mRNA vaccine candidate developed on this platform demonstrated an immune response at a level similar to that of existing global vaccines in non-clinical studies. The company also reported obtaining results from non-clinical safety evaluations that support continued development. However, these findings derive from animal studies or experimental settings, and actual safety and preventive efficacy in humans must be verified through future clinical trials.
The company completed the first administration to a subject in its Phase 1 clinical trial at the end of January 2026. Submission of a Phase 2 clinical trial plan is targeted for the second half of this year.
End-to-End Manufacturing Independence
GC Green Cross (search) stated that it has established a system enabling it to independently perform all stages of vaccine development and production. This end-to-end capability spans cell line development, mRNA synthesis, LNP formulation, finished product manufacturing, and quality analysis. The company indicated that this integrated infrastructure is designed to shorten the time required from candidate design to production in the event of an infectious disease outbreak.
Jung Jae-wook, head of R&D at GC Green Cross (search), said, "Based on our accumulated mRNA research capabilities and production infrastructure, we are building a foundation for rapid response to future pandemics," adding, "We will continue research to secure vaccine development competitiveness at a global level."